Lilly Releases Early-Stage Pipeline Data at AACR Annual Meeting 2015
Eli Lilly and Company will present early-stage data from several targeted cancer therapies, reflecting Lilly's diverse oncology pipeline, during the American Association for Cancer Research (AACR) Annual Meeting 2015, held April 1822 April in Philadelphia, PA.
"Bringing Cancer Discoveries to Patients" is the theme of this year's AACR meeting and one that is mirrored through Lilly's commitment to broadening its portfolio of therapies that accelerate the pace and progress of cancer care. Lilly research to be presented at AACR represents findings from several of its oncology pipeline compounds in various stages of development.
"The research we present at AACR will set the stage for the next generation of therapies from Lilly," said Richard Gaynor, senior vice president of product development and medical affairs for Lilly Oncology. "Each step we take in the course of our research — both in the lab and in clinical trials — leads us toward the same overall goal: to increase the number of life-changing medicines and innovative solutions available to patients."
Titles of the presented abstracts are as follows:
• Abstract #3101: In-vitro characterization of abemaciclib pharmacology in ER+ breast cancer cell lines
• Abstract #CT240: Checkpoint Kinase (CHK) 1/2 Inhibitor LY2606368 in a Phase I Dose-Expansion Study in Patients with Squamous Cell Carcinoma of the Head and Neck
• Abstract #2142: Novel Oncogenic BRaf Deletions Functioning as BRaf Homodimer and Sensitive to Inhibition by LY3009120, a Pan Raf and Raf Dimer Inhibitor
Related News
-
News BioNTech to begin mRNA vaccine manufacturing in Rwanda by 2025
German biotechnology company BioNTech has stated their intentions to begin production at their mRNA vaccine factory in Rwanda by 2025, which will mark the first foreign mRNA vaccine manufacturing site on the continent of Africa. -
News Identifying Alzheimer’s Disease biomarker proteins with whole blood tests
A University of Manchester spin-out pharmaceutical company, PharmaKure, has reported successful study results for the quantification of Alzheimer’s Disease biomarker proteins with a whole blood test. -
News Bill & Melinda Gates Foundation to boost mRNA vaccine initiatives in Africa with USD $40m
To address vaccine inequality and accessibility issues, the Bill & Melinda Gates Foundation aims to deliver USD $40m to various biotech companies and vaccine manufacturers in support of mRNA vaccine development. -
News CPHI Podcast Series: Exploring neurological frontiers in Alzheimer's and beyond
The next episode of the CPHI Podcast Series delves into the science and background behind some recent developments in the field of Alzheimer's disease and neurological disorders. -
News Is patient centricity the future of pharmaceutical manufacturing?
In this interview with Sandra Sánchez y Oldenhage, President of PharmAdvice, she speaks to the importance of considering patients in the manufacturing stages of the pharmaceutical supply chain, and how it can redefine healthcare. -
News CPHI Podcast Series: How to leverage AI for Drug Discovery
Artificial intelligence is the topic of debate in the latest episode from the CPHI Podcast Series, where Digital Editor Lucy Chard speaks with Bill Whitford of DPS Group about the integration of AI in healthcare. -
News Pfizer forges ahead with blood cancer therapy after approval from FDA
Pfizer gains accelerated approval from the US FDA for their new bispecific antibody therapy for multiple myeloma, set to address an unmet need for patients. -
News Alzheimer's drug donanemab deemed effective in landmark clinical trial
Results from the TRAILBLAZER-ALZ 2 Randomised Clinical Trial into the use of donanemab to treat early symptoms of Alzheimer’s disease have been analysed.
Position your company at the heart of the global Pharma industry with a CPHI Online membership
-
Your products and solutions visible to thousands of visitors within the largest Pharma marketplace
-
Generate high-quality, engaged leads for your business, all year round
-
Promote your business as the industry’s thought-leader by hosting your reports, brochures and videos within your profile
-
Your company’s profile boosted at all participating CPHI events
-
An easy-to-use platform with a detailed dashboard showing your leads and performance